MaridebartMaridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

Sponsor:

Amgen

Code:

NCT07037459

Conditions

Heart Failure With Preserved Ejection Fraction

Heart Failure With Mildly Reduced Ejection Fraction

Obesity

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Maridebart cafraglutide

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-20. This information was provided to ClinicalTrials.gov by Amgen on 2026-07-02.